- This information is intended for US Healthcare Professionals only.
Resource Library
Please see below for videos about immuno-oncology pathways, unmet needs in the management of bladder cancer, and expert points of view on the treatment and management of imAEs.
Chapters: 3
Total Time: 01:44
| 1. | Introduction to imAEs 00:00 |
| 2. | imAE management 00:34 |
| 3. | imAE treatment with corticosteroids 01:09 |
Chapters: 5
Total Time: 07:28
| 1. | Introduction to endocrinopathies 00:00 |
| 2. | Diagnosing thyroiditis 00:57 |
| 3. | Diagnostic concerns with IO thyroiditis 02:57 |
| 4. | Other endocrinopathies 04:05 |
| 5. | Treating endocrinopathies 06:17 |
Chapters: 6
Total Time: 06:33
| 1. | Introduction to diarrhea and colitis 00:00 |
| 2. | Concerns when diagnosing colitis 01:54 |
| 3. | Diagnosing colitis in IO 02:20 |
| 4. | Grading colitis 03:45 |
| 5. | Treating colitis 04:44 |
| 6. | Treating steroid-resistant colitis 05:45 |
Chapters: 6
Total Time: 05:26
| 1. | Introduction to nephritis 00:00 |
| 2. | Testing for nephritis 01:34 |
| 3. | Diagnosing nephritis 02:21 |
| 4. | Treating nephritis 03:08 |
| 5. | Retreating after nephritis 04:35 |
| 6. | Effect of treatment on IO efficacy 05:12 |
Chapters: 6
Total Time: 04:38
| 1. | Introduction to hepatitis in IO 00:00 |
| 2. | Diagnosing hepatitis in IO 00:55 |
| 3. | Concerns when diagnosing hepatitis 01:35 |
| 4. | Treating hepatitis in IO 02:37 |
| 5. | Treating hepatitis with steroids 03:29 |
| 6. | Efficacy of IO during imAE treatment 04:07 |
Chapters: 5
Total Time: 04:03
| 1. | Introduction to pneumonitis 00:00 |
| 2. | Diagnosing pneumonitis 01:22 |
| 3. | Additional tests for suspected pneumonitis 02:18 |
| 4. | Treating suspected pneumonitis 02:39 |
| 5. | Treating pneumonitis with steroids 03:20 |
Chapters: 8
Total Time: 07:50
| 1. | Introduction to skin reactions 00:00 |
| 2. | Blistering skin reaction 01:09 |
| 3. | Treating Grade 1 skin reactions 01:57 |
| 4. | Treating Grade 2 skin reactions 03:01 |
| 5. | Treating severe skin reactions 04:00 |
| 6. | Treatment of steroid-refractory patients 05:01 |
| 7. | Efficacy concerns in managing imAEs 05:43 |
| 8. | Skin reactions in summary 06:43 |
Total Time: 02:55
Total Time: 02:20
Total Time: 02:17
Total Time: 02:15
Total Time: 15:54
Introduction to imAEs
Endocrine system
Gastrointestinal tract
Kidneys
Liver
Lungs
Skin
What is the rationale for combining PD-L1 inhibition and CTLA-4 inhibition?
Inhibiting the PD-1/PD-L1 pathway
CTLA-4 inhibition
Activating the OX40/OX40L axis
What is the rationale for combining PD-L1 inhibition and CTLA-4 inhibition?
Inhibiting the PD-1/PD-L1 pathway
CTLA-4 inhibition
Activating the OX40/OX40L axis
Unmet needs in the management of bladder cancer
“As immuno-oncology treatments multiply, one challenge is learning to recognize and manage unique immune-mediated adverse events.”
— Dr Antonia
“Patients should be counseled, educated on those sorts of symptoms to look out for and report, because those symptoms may occur before we as treating physicians are aware of it based on blood abnormalities.”
— Dr Antonia
“The activation of the immune system can generate a number of so-called immune-related adverse events. And I would say the most common one is colitis.”
— Dr Maio
“Immune-related nephritis is, luckily, a fairly rare scenario. It occurs well under 1% of the time.”
— Dr Weber
“Hepatitis is almost always asymptomatic and that is why we always incorporate blood tests and liver function tests into our workups.”
— Dr Antonia
“If we intervene early with steroids, we often, and rarely, I would say, need to go to the next step, that is higher-dose steroids with longer taper.”
— Dr Cohen
“What we tell patients about skin reactions is that this tends to be one of the earlier side effects they may notice.”
— Dr Cohen
PD-1=programmed cell death-1; PD-L1=programmed cell death ligand-1; CTLA-4=cytotoxic T-lymphocyte-associated antigen-4; NSCLC=non-small cell lung cancer.
